Article Text

Download PDFPDF

Review: chlorpromazine reduces relapse but increases adverse events in schizophrenia

Statistics from

Question In schizophrenia, to what extent does chlorpromazine reduce symptoms, relapse, and discontinuation of medication, and how frequent are the most common adverse events?

Data sources

Studies were identified by searching Biological Abstracts, Cochrane Schizophrenia Group's Register, The Cochrane Library, EMBASE, Medline, PsycLIT, and SCISEARCH; by scanning the bibliographies of identified articles; and by contacting pharmaceutical companies and authors of trials.

Study selection

Studies were selected if they were randomised controlled trials investigating the effectiveness of chlorpromazine compared with placebo or no treatment in patients with schizophrenia.

Data extraction

Data were extracted on patient characteristics, drug dose, and primary outcomes of interest: death, relapse, overall improvement, discontinuation …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles